Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792838 | 0.86 | TAAR1 (0.54) | HRH3TAAR1LOXL2 | |
| SCHEMBL3785928 | 0.84 | NOS1 (0.47) | TAAR1NOS3NOS1NOS2LOXL2 | |
| SCHEMBL260102 | 0.80 | HRH3 (0.74) | HRH3TAAR1AKT2CYP2A6ADRB2 | |
| SCHEMBL28223278 | 0.79 | HRH3 (0.82) | HRH3TAAR1CYP2A6ADRB2LOXL2 | |
| SCHEMBL3786652 | 0.79 | TAAR1 (0.61) | HRH3TAAR1AKT2NOS3NOS1 | |
| SCHEMBL27817084 | 0.78 | NOS1 (0.48) | TAAR1NOS3NOS1NOS2LOXL2 | |
| SCHEMBL43251 | 0.77 | ALDH1A1 (0.47) | HRH3TAAR1CYP2A6LOXL2 | |
| SCHEMBL12968186 | 0.77 | PGK1 (0.42) | HRH3TAAR1NOS3NOS1NOS2 | |
| SCHEMBL2274647 | 0.76 | HRH3 (1.00) | HRH3TAAR1CYP2A6ADRB2LOXL2 | |
| SCHEMBL27651134 | 0.75 | HRH3 (0.58) | HRH3TAAR1AKT2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HRH3 169/4885TAAR1 1746/4885AKT2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.